Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 18, 2020 - Issue 6
Submit an article Journal homepage
4,348
Views
21
CrossRef citations to date
0
Altmetric
Review

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

N.S. Nurmohameda Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands;b Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-9045-6009View further author information
ORCID Icon,
G.M. Dallinga – Thiea Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-5412-5923View further author information
ORCID Icon &
E.S.G. Stroesa Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The NetherlandsCorrespondence[email protected]
View further author information
Pages 355-361 | Received 24 Jan 2020, Accepted 11 May 2020, Published online: 08 Jun 2020

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Isabel Shamsudeen & Robert A. Hegele. (2022) Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology 15:4, pages 395-405.
Read now
Kristen J. Bubb, Adam J. Nelson & Stephen J. Nicholls. (2022) Targeting triglycerides to lower residual cardiovascular risk. Expert Review of Cardiovascular Therapy 20:3, pages 185-191.
Read now

Articles from other publishers (19)

Malihe Aghasizadeh, Mahmoud Ghanei, Sahar Ghoflchi, Parisa Asadian-sohan, Mohammad Haghani, Tooba Kazemi, Habibollah Esmaily, Amir Avan, Gordon A. Ferns, Ebrahim Miri-Moghaddam & Majid Ghayour-Mobarhan. (2023) Association of Genotypes of ANGPTL3 with Vitamin D and Calcium Concentration in Cardiovascular Disease. Biochemical Genetics.
Crossref
Shaunak Mangeshkar, Natalia Nazarenko, Dimitrios Varrias, Michail Spanos, Pawel Borkowski, Majd Al Deen Alhuarrat, Weijia Li, Preeti Kishore & Robert T Faillace. (2023) A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment. Cureus.
Crossref
Xavier Pintó, Marta Fanlo, Virginia Esteve & Jesús Millán. (2023) Remnant cholesterol, vascular risk, and prevention of atherosclerosis. Clínica e Investigación en Arteriosclerosis (English Edition) 35:4, pages 206-217.
Crossref
Ronald M. Krauss, Jonathan T. Lu, Joseph J. Higgins, Cathryn M. Clary & Ray Tabibiazar. (2023) VLDL receptor gene therapy for reducing atherogenic lipoproteins. Molecular Metabolism 69, pages 101685.
Crossref
桢婷 关. (2023) Study on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein. Advances in Clinical Medicine 13:03, pages 3424-3430.
Crossref
Angelo B. Cefalù, Laura D'Erasmo, Gabriella Iannuzzo, Davide Noto, Antonina Giammanco, Anna Montali, Alberto Zambon, Francesco Forte, Patrizia Suppressa, Stefano Giannini, Carlo M. Barbagallo, Antonina Ganci, Emilio Nardi, Federica Vernuccio, Rosalia Caldarella, Marcello Ciaccio, Marcello Arca & Maurizio Averna. (2022) Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis 359, pages 13-19.
Crossref
Saverio Muscoli, Mihaela Ifrim, Massimo Russo, Francesco Candido, Angela Sanseviero, Marialucia Milite, Marco Di Luozzo, Massimo Marchei & Giuseppe Massimo Sangiorgi. (2022) Current Options and Future Perspectives in the Treatment of Dyslipidemia. Journal of Clinical Medicine 11:16, pages 4716.
Crossref
Clarice Gareri, Alberto Polimeni, Salvatore Giordano, Laura Tammè, Antonio Curcio & Ciro Indolfi. (2022) Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. Journal of Clinical Medicine 11:13, pages 3884.
Crossref
Yonglang Cheng, Tongxi Li, Peng Tan, Yichao Du, Zhiwei Huang, Hao Shi, Tianying Cai, Yifan Chen & Wenguang Fu. (2022) Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. Endocrine 76:2, pages 253-262.
Crossref
Jing Pang, Stephen C.H. Li, Dick C. Chan, David R. Sullivan, Ann-Marie Woodward & Gerald F. Watts. (2022) Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry. Current Opinion in Endocrinology, Diabetes & Obesity 29:2, pages 131-140.
Crossref
Isabel Shamsudeen & Robert A. Hegele. (2022) Advances in the care of lipodystrophies. Current Opinion in Endocrinology, Diabetes & Obesity 29:2, pages 152-160.
Crossref
Chris J. Packard. (2022) Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease. Current Atherosclerosis Reports 24:3, pages 133-142.
Crossref
晓敏 杨. (2022) Progress in the Pathogenesis and Treatment of Hyperlipidemia Acute Pancreatitis. Advances in Clinical Medicine 12:05, pages 4788-4794.
Crossref
Yan-yan Qi, Li Yan, Zhong-min Wang, Xi Wang, Hua Meng, Wen-bo Li, Dong-chang Chen, Meng Li, Jun Liu & Song-tao An. (2021) Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis. Diabetology & Metabolic Syndrome 13:1.
Crossref
James M Backes & Daniel E Hilleman. (2021) New and emerging lipid-lowering therapy. Future Cardiology 17:8, pages 1407-1420.
Crossref
Radu Sascău, Alexandra Clement, Rodica Radu, Cristina Prisacariu & Cristian Stătescu. (2021) Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review. Nutrients 13:6, pages 1774.
Crossref
Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos Kypreos & Theodosios D. Filippatos. (2021) ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports 23:5.
Crossref
Gissette Reyes-Soffer. (2021) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Current Opinion in Endocrinology, Diabetes & Obesity 28:2, pages 85-89.
Crossref
Ronald B. Goldberg & Alan Chait. (2020) A Comprehensive Update on the Chylomicronemia Syndrome. Frontiers in Endocrinology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.